Biotech Late Stage Investors & VC Firms
360 firms in this list, with a median first check of $1M. 82 of them lead rounds. Generated from verified public data and updated continuously.
Nordic Capital
StockholmGrowth–Late Stage
13 people
HealthQuest Capital
Redwood CityGrowth–Late Stage
14 people
Crescent Capital Partners
SydneyGrowth–Late Stage$13.2M – $52.8M
24 people
Omega Funds
BostonSeed–Late Stage
19 people
Magnum Industrial Partners Tres S.L.
MadridGrowth–Late Stage
17 people
Thorney Investment Group
MelbourneSeed–Late Stage
25 people
Black Opal Ventures
New YorkSeed–Late Stage
18 people
Oberland Capital
New YorkGrowth–Late Stage
20 people
New Alliance Capital
ShanghaiSeed–Late Stage
25 people
MSD Global Health Innovation Fund
RahwaySeries A–Late Stage$2M – $10M
10 people
Creathor Ventures
Bad HomburgSeed–Late Stage$540K – $10.8M
2 people
Crossbeam Venture Partners
New YorkPre-Seed–Late Stage$1M – $1.5M
8 people
Keensight Capital
ParisGrowth–Late Stage$10M – $800M
4 people
DNA Capital
São PauloSeed–Late Stage$100K – $5M
15 people
Invus
New YorkSeed–Late Stage
8 people
HBM Partners
ZugSeed–Late Stage$5M – $50M
6 people
Pappas Capital
Research Triangle ParkSeed–Late Stage$100K – $6M
15 people
JK&B Capital
ChicagoSeed–Late Stage
9 people
Ally Bridge Group
New YorkGrowth–Late Stage
7 people
CPT Capital
LondonPre-Seed–Late Stage
7 people
Rock Springs Capital
BaltimoreLate Stage
13 people
BrightEdge
AtlantaPre-Seed–Late Stage
15 people
Darwin Venture Management
TaipeiSeed–Late Stage$1M – $5M
19 people
New Science Ventures
GreenwichSeed–Late Stage$2M – $8M
7 people
Related lists
Biotech Investors & VC Firms (2585)Biotech Seed Investors & VC Firms (2105)Late Stage Investors & VC Firms (1710)Biotech Series A Investors & VC Firms (1693)Biotech Investors & VC Firms in North America (1688)Biotech Investors & VC Firms in United States (1535)Biotech Investors & VC Firms in Europe (990)Biotech Pre-Seed Investors & VC Firms (987)Late Stage Investors & VC Firms in North America (915)Biotech Investors & VC Firms in Global (887)
Data sourced from public filings and firms' own websites — see our methodology.
































































































